Corinne Hanotin

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Vera Bittner, Michael Szarek, Philip E. Aylward et al. · Journal of the American College of Cardiology · 2020 · 572 citations · Full text

Medicine, Cardiology, Pharmacology +17

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

James M. McKenney, Michael J. Koren, Dean J. Kereiakes et al. · Journal of the American College of Cardiology · 2012 · 507 citations

Pharmacy, Cardiology, Pharmacotherapy +13

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

Eli M. Roth, James M. McKenney, Corinne Hanotin et al. · New England Journal of Medicine · 2012 · 464 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan et al. · American Heart Journal · 2014 · 411 citations · Full text

Medicine, Cardiology, Pharmacology +17